Gordon Guyatt's Confession: What the Father of Evidence-Based Medicine Didn't Read (#36)
Gordon Guyatt invented the framework that underpins NICE guidelines and the Cass Review. His own systematic reviews found only low-quality evidence for paediatric gender interventions — yet he admits, in this explosive interview, to signing an advocacy statement endorsing such care without reading it. For British listeners who have watched NHS policy reshape itself in the wake of Cass and the Tavistock closure, his candour about the gap between rigorous evidence and real-world advocacy could not be more timely.
Gordon Guyatt is not a name most people outside medicine would recognise, but his fingerprints are on almost every clinical decision made in the modern NHS. In 1991, as a professor at McMaster University in Canada, he coined the term evidence-based medicine and created the hierarchy of evidence — the pyramid of randomised trials, systematic reviews and meta-analyses — that NICE relies on when assessing treatments for NHS commissioning. His User's Guide to the Medical Literature became the standard text for clinicians worldwide. When Guyatt's team turned that same rigorous apparatus on paediatric gender medicine, they found only low-quality evidence for the interventions being offered to children and adolescents. That conclusion matters acutely in Britain. The Cass Review, published in 2024, reached an almost identical verdict after its own evidence sweep — and it was partly on that basis that NHS England suspended puberty blockers for under-18s outside research settings and announced the closure of the Tavistock's Gender Identity Development Service. Guyatt's systematic reviews were, in effect, providing the international scaffolding for what Cass confirmed closer to home. The episode's central revelation, however, concerns not what Guyatt found but what he signed. When twenty American states drew on his reviews to restrict access to gender treatments for minors, he publicly denounced it as an egregious, unconscionable misuse of his work. Pressed in this interview on a statement he had co-signed endorsing medically necessary care for gender diverse youth, he makes a remarkable admission: he had not read the relevant paragraph carefully before adding his name. "That was not my paragraph, and I didn't read carefully enough," he says. And then: "I was a dope. Okay. I'm sometimes a dope." The interview also exposes a telling tension in how Guyatt positions himself. He repeatedly insists he is a total non-expert in this area — paediatric gender medicine specifically — while simultaneously lending his name and reputation to advocacy statements about it. When asked whether adolescents can meaningfully consent to interventions affecting their future fertility, he deflects, drawing instead on his experience with cognitively impaired elderly patients. The hosts note that society does not routinely offer vasectomies or tubal ligations to teenagers as contraception. Guyatt does not engage the comparison directly. For a British audience, this matters beyond the biographical. The entire architecture of NHS clinical decision-making — from NICE technology appraisals to the commissioning guidance that followed Cass — rests on exactly the framework Guyatt built. When the architect of evidence-based medicine cannot apply it consistently to a contested clinical area, and when advocacy pressure proves capable of outrunning his own stated principles, it illuminates the environment in which British clinicians, commissioners and policymakers have been operating for more than a decade. The Tavistock did not collapse in a vacuum. The hosts — Stella O'Malley, Mia Hughes and Dr Bret Alderman — press Guyatt on the parallel with bone marrow transplants for breast cancer, a cautionary episode in which patient advocates demanded access to a treatment that ultimately proved harmful. Guyatt grows defensive, saying he feels manipulated. The discomfort itself is instructive: evidence-based medicine, its founder included, has found paediatric gender medicine a uniquely difficult case to handle with dispassion.
